Testosterone for women: what the science actually says

Testosterone is often marketed to women as a fix for low desire, low energy, low mood, and foggy thinking. The evidence is much narrower. No systemic testosterone product is FDA-approved for women in the United States, and consensus guidance supports consideration only for carefully assessed hypoactive sexual desire disorder, not as a general menopause or wellness treatment. ^{2, 3}

The short version: Women make testosterone, but a blood level does not diagnose sexual dysfunction. The best-supported use is postmenopausal hypoactive sexual desire disorder that causes distress after a biopsychosocial assessment. Any treatment is off-label, clinician-directed, and monitored to keep levels in the normal premenopausal range. ^{2, 3}

Testosterone is produced in women's ovaries and adrenal glands, and levels generally change with age. ISSWSH cautions that no testosterone concentration separates women with HSDD from women without it. Symptoms and a biopsychosocial assessment, rather than a target blood number, drive the diagnosis. ³

Here is where careful reading matters. There is genuine, high-quality evidence for testosterone in women, but it covers a much smaller territory than the internet suggests. The strongest support is for one specific situation. Most of the other promises do not yet have the research to back them.

No systemic testosterone product is FDA-approved for women in the United States. ISSWSH describes treatment as off-label and clinician-directed, with informed consent, physiologic-range monitoring, and review of formulation-specific risks. Compounded products, pellets, intramuscular injections, and oral formulations are not recommended by the guideline. ³

ISSWSH recommends that clinicians measure total testosterone and SHBG before treatment, recheck total testosterone 3 to 6 weeks after initiation, assess response and androgen excess, and monitor levels every 4 to 6 months once stable. If there is no clinically meaningful improvement, the guideline says treatment should not continue beyond 6 months. ³

Flibanserin (Addyi) is a daily prescription tablet approved for women younger than 65 with acquired, generalized HSDD that is not due to another condition, medication, or relationship problem. Its label includes important alcohol and drug-interaction precautions because of severe hypotension and fainting risk. ¹

The hormone gap is real, and that is exactly why it attracts bad actors. When demand is high and approved products are missing, marketing rushes into the gap. The way to protect yourself is to know what good care sounds like.

Bring the symptom, not a requested product, to a licensed clinician. Ask what other contributors were assessed, what evidence supports the proposed option, how response and adverse effects will be monitored, and when treatment would stop if it does not help.